MONTREAL, Feb. 14, 2014 /CNW Telbec/ - The Centre hospitalier de l'Université de Montréal Research Centre (CRCHUM) has received $18.4 million in public- and
private-sector funding to carry out the Opti-Thera program.
This research program, established by CRCHUM researchers in
collaboration with colleagues from the Université de Montréal Faculty of Pharmacy, Centre hospitalier universitaire Sainte-Justine and McGill University Health Centre Research Ethics Board, is aimed at
promoting the development of personalized medicine in Quebec. The
project will also bring in researchers from Université de Montréal's Centre de médecine génique communautaire at Chicoutimi hospital in order to ensure the development of knowledge
and quick application of the project's findings in the regions.
"I am very pleased to be co-lead on this Opti-Thera project," said Dr.
Jacques Turgeon, Director of the CRCHUM. "This research will not only
help better prevent certain diseases like type-2 diabetes, it will also
make it possible to more effectively treat illnesses in general by
determining drug therapy on the basis of a patient's genetic
The Opti-Thera program—for Optimization of Therapeutic Approaches in
Personalized Primary Care—is the fruit of solid collaboration between
the university and private sectors. The research conducted will serve
to establish news strategies for optimizing frontline drug therapies
among patients suffering from cardiometabolic diseases. Over the longer
range, these advances will benefit all medical specializations.
"Opti-Thera is a unique opportunity for us to incorporate the advances
in applied genomics into health and the environment and thereby ensure
health professionals have better tools at their disposal to maintain
and improve the health of their patients. This new trend toward
personalized healthcare is aimed at preventing disease and
significantly relieving the burden on public healthcare spending,"
added Dr. Pavel Hamet, CRCHUM researcher and Opti-Thera program lead.
The Fonds de partenariat pour un Québec innovant et en santé, a government-funded initiative that supports cost-sharing projects
between biopharmaceutical companies and public research bodies, is
investing $9.2 million in the project. This amount is matched by a
group of private partners consisting of pharmaceutical and
biotechnology companies, software development firms and other
enterprises (Servier France and Canada, Pfizer Canada, Valeant Canada,
Affymetrix, Ariana Pharma, Novartis, Familiprix, Écogène 21,
Medpharmgene and InterMED-Rx).
This wide-scale research program brings together a group of research
specialists whose complementary expertise promises to help
revolutionize the medical world of tomorrow. For a full list of the
Opti-Thera research team and collaborators, visit: http://depotcrchum.mtl.rtss.qc.ca/Public/OPTI-THERA.Equipe_eng.pdf.
The Centre hospitalier de l'Université de Montréal Research Centre (CRCHUM) is dedicated to improving adult health through
a continuum of high-level research activities that lead to a better
understanding of etiological and pathogenic mechanisms and promote the
development, implementation and assessment of new preventive,
diagnostic and therapeutic strategies. The Centre offers a stimulating
training environment that paves the way for continuity in the search
for excellence. www.crchum.qc.ca
SOURCE: Centre hospitalier de l'Université de Montréal
For further information:
Communications Advisor - Media Relations
514 890-8000, ext. 15262
514 860-7110 (pager)
Assistant Director, Information and Development
CHUM Research Centre
514 890-8000 ext. 14090